Table 6.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	52	79	89	139	134	167	180	158	183	197
With Immunosuppression Info	50	76	81	135	128	165	177	153	176	190
Induction Drugs										
ALG	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	22.0%	18.4%	14.8%	8.1%	0.0%	0.0%	0.0%	1.3%	2.3%	0.0%
OKT3	44.0%	39.5%	22.2%	7.4%	4.7%	3.0%	2.8%	0.7%	0.0%	1.6%
Thymoglobulin	0.0%	0.0%	0.0%	30.4%	48.4%	49.1%	59.9%	45.1%	51.1%	48.4%
Zenapax	0.0%	1.3%	30.9%	30.4%	44.5%	34.5%	30.5%	7.8%	9.1%	5.3%
Simulect	0.0%	0.0%	3.7%	11.1%	9.4%	3.0%	4.0%	6.5%	0.0%	2.1%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	32.0%	42.0%	33.7%
No Induction Drugs Recorded	32.0%	40.8%	42.0%	37.0%	29.7%	38.8%	31.1%	18.3%	19.3%	16.3%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.